Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 06, 2019 08:00 ET | Source: Momenta Pharmaceuticals, Inc.

Momenta Pharmaceuticals to Webcast Presentation at Two Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat...
October 31, 2019 07:00 ET | Source: Momenta Pharmaceuticals, Inc.

Momenta Pharmaceuticals Reports Third Quarter 2019 Financial and Operating Results

CAMBRIDGE, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat...
October 17, 2019 08:00 ET | Source: Momenta Pharmaceuticals, Inc.

Momenta Pharmaceuticals Announces Date of Third Quarter 2019 Financial Results Conference Call and Webcast

CAMBRIDGE, Mass., Oct. 17, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat...
September 19, 2019 08:00 ET | Source: Momenta Pharmaceuticals, Inc.

Momenta Pharmaceuticals Appoints Dr. Donna Grogan to Board of Directors

CAMBRIDGE, Mass., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat...
August 02, 2019 07:00 ET | Source: Momenta Pharmaceuticals, Inc.

Momenta Pharmaceuticals Reports Second Quarter 2019 Financial and Operating Results

— Launches adaptive Phase 2/3 study of nipocalimab (M281) in Warm Autoimmune Hemolytic Anemia (wAIHA), the Company’s third study of its FcRn inhibitor; top-line data expected by end of 2021 — —...
August 01, 2019 16:05 ET | Source: Momenta Pharmaceuticals, Inc.

Momenta Pharmaceuticals Launches Phase 2/3 Trial of M281 for the Treatment of Warm Autoimmune Hemolytic Anemia and is Granted FDA Fast Track Designation

CAMBRIDGE, Mass., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat...
July 30, 2019 07:00 ET | Source: Momenta Pharmaceuticals, Inc.

Momenta Pharmaceuticals Announces Fast Track Designation for M281 (nipocalimab) in Hemolytic Disease of the Fetus and Newborn (HDFN)

CAMBRIDGE, Mass., July 30, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat...
July 19, 2019 08:00 ET | Source: Momenta Pharmaceuticals, Inc.

Momenta Pharmaceuticals Announces Date of Second Quarter 2019 Financial Results Conference Call and Webcast

CAMBRIDGE, Mass., July 19, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat...
June 19, 2019 08:00 ET | Source: Momenta Pharmaceuticals, Inc.

Momenta Pharmaceuticals Announces Settlement Agreement with Amphastar Resolving Enoxaparin Sodium Injection Litigation

CAMBRIDGE, Mass., June 19, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat...
June 04, 2019 07:30 ET | Source: Momenta Pharmaceuticals, Inc.

Momenta Pharmaceuticals to Webcast Presentation at the Goldman Sachs 40th Annual Global Healthcare Conference

CAMBRIDGE, Mass., June 04, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right